A
ABIONYX
Biotech & Life Sciences · Balma, France · Founded 2005 · IPO 2015
Developing of novel therapies for the treatment of cardiovascular and metabolic diseases MoreLess
ABIONYX Pharma is a cutting-edge biotech company focused on discovering and developing innovative therapies for patients who currently lack effective treatment options. The company operates in the biotechnology sector, specifically targeting cardiovascular diseases and associated metabolic disorders such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). ABIONYX also explores HDL-targeted drug delivery platforms in the field of oncology, particularly immuno-oncology. The business model involves leveraging existing development assets inherited from CERENIS Therapeutics and forming strategic partnerships to advance its research and development activities. ABIONYX generates revenue through the development and commercialization of its proprietary therapies and drug delivery platforms.
Keywords: biotech, cardiovascular diseases, metabolic disorders, NAFLD, NASH, HDL-targeted, drug delivery, oncology, immuno-oncology, innovative therapies.
Company overview
ABIONYX company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2005
- Headquarters
- Balma, France
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 28.0
- Investment activity
- 1 companies · latest Nov 2017
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
ABIONYX funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jun 2026 | $36M | — | Fenja Capital | ↗ |
| POST IPO EQUITYOther financing | Dec 2025 | $2M | — | Undisclosed | ↗ |
| GRANTOther financing | Mar 2024 | $1.1M | — | Bpifrance | ↗ |
| PRIVATE PLACEMENT VCOther financing | Dec 2021 | $4.6M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Jul 2018 | $1.2M | — | Undisclosed | — |
| IPOOther financing | Mar 2015 | Undisclosed | — | ||
| SERIES COther financing | Jul 2010 | Sofinnova Partners · EDF Ventures · OrbiMed · Alta Partners | — | ||
| SERIES BOther financing | Nov 2006 | Sofinnova Partners · Alta Partners · EDF Ventures · OrbiMed | — | ||
| SERIES AOther financing | Aug 2005 | HealthCap · Sofinnova Partners · Alta Partners · EDF Ventures | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $5.1M | +14.7% | −$21M | -408.2% |
| 2025 | $4.5M | -10.7% | −$5.7M | -127.7% |
| 2024 | $5M | -1.9% | −$4.5M | -89.4% |
| 2023 | $5.1M | -11.7% | −$3.4M | -66.8% |
| 2022 | $5.8M | +678.1% | −$4.4M | -76.4% |
| 2021 | $743K | — | −$6.3M | -843.7% |
| 2020 | $0 | — | −$2.1M | — |
Growth signals
ABIONYX website traffic
Latest recorded traffic for ABIONYX is 3.7K monthly website visits, up 117.6% over the last three months.
Comparisons
ABIONYX compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
ABIONYX investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
ABIONYX's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where ABIONYX has talent and traffic
team presence
In the news
Latest news about ABIONYX
Recent press, funding announcements, and product moves mentioning ABIONYX — open to read from the original sources.
Market sentiment
What the market is saying about ABIONYX
An AI-synthesized read of the highest-engagement posts about ABIONYX on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ABIONYX’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.